Company Overview: GSK

GSK Overview

Upcoming Projects (GSK)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (GSK)

Discussing the current landscape of the seasonal flu, COVID-19, and various vaccinations.
Tickers: GSK, SNY, AZN
Executed On: Oct 01, 2024 at 10:00 AM EDT
A Third Look: Discussing the expanded approval of Jemperli (dostarlimab) plus chemotherapy for all adult patients with primary advanced or recurrent endometrial cancer, including MMRp/MSS tumors
Ticker: GSK
Executed On: Sep 26, 2024 at 01:00 PM EDT
Third View: Discussing GSK's recent positive data from Phase II seasonal influenza mRNA vaccine programme.
Ticker: GSK
Executed On: Sep 26, 2024 at 10:00 AM EDT
Second View: Discussing GSK's recent positive data from Phase II seasonal influenza mRNA vaccine programme.
Ticker: GSK
Executed On: Sep 19, 2024 at 05:30 PM EDT
A Second Look: Discussing the expanded approval of Jemperli (dostarlimab) plus chemotherapy for all adult patients with primary advanced or recurrent endometrial cancer, including MMRp/MSS tumors
Ticker: GSK
Executed On: Sep 18, 2024 at 04:00 PM EDT
Discussing GSK's recent positive data from Phase II seasonal influenza mRNA vaccine programme.
Ticker: GSK
Executed On: Sep 18, 2024 at 08:30 AM EDT
A Third Look: Discussing the results from the SWIFT-1 and SWIFT-2 phase III clinical trials of depemokimab in adults and adolescents with severe asthma with type 2 inflammation characterized by raised blood eosinophil count.
Ticker: GSK
Executed On: Sep 17, 2024 at 08:00 AM EDT
A Second Look: Discussing the results from the SWIFT-1 and SWIFT-2 phase III clinical trials of depemokimab in adults and adolescents with severe asthma with type 2 inflammation characterized by raised blood eosinophil count.
Ticker: GSK
Executed On: Sep 16, 2024 at 01:00 PM EDT
Discussing the results from the SWIFT-1 and SWIFT-2 phase III clinical trials of depemokimab in adults and adolescents with severe asthma with type 2 inflammation characterized by raised blood eosinophil count.
Ticker: GSK
Executed On: Sep 16, 2024 at 09:00 AM EDT
Speaking with a third physician who has experience using GSK's Shingrix vaccine for the prevention of herpes zoster (HZ) (shingles) in patients 50 years and older.
Ticker: GSK
Executed On: Sep 11, 2024 at 01:30 PM EDT
Discussing the expanded approval of Jemperli (dostarlimab) plus chemotherapy for all adult patients with primary advanced or recurrent endometrial cancer, including MMRp/MSS tumors
Ticker: GSK
Executed On: Sep 10, 2024 at 01:30 PM EDT
Speaking with a second physician who has experience using GSK's Shingrix vaccine for the prevention of herpes zoster (HZ) (shingles) in patients 50 years and older.
Ticker: GSK
Executed On: Aug 29, 2024 at 01:30 PM EDT
Speaking with a physician who has experience using GSK's Shingrix vaccine for the prevention of herpes zoster (HZ) (shingles) in patients 50 years and older.
Ticker: GSK
Executed On: Aug 28, 2024 at 09:30 AM EDT
A Third Look: Discussing the PASO DOBLE (GeSIDA 11720 study), the largest head-to-head, phase IV randomised clinical trial (RCT) investigating the 2-drug regimen Dovato compared to the 3-drug regimen Biktarvy for the treatment of HIV-1
Tickers: GSK, GILD
Executed On: Aug 22, 2024 at 03:00 PM EDT
A Second Look: Discussing the PASO DOBLE (GeSIDA 11720 study), the largest head-to-head, phase IV randomised clinical trial (RCT) investigating the 2-drug regimen Dovato compared to the 3-drug regimen Biktarvy for the treatment of HIV-1
Tickers: GSK, GILD
Executed On: Aug 01, 2024 at 04:00 PM EDT
Discussing the PASO DOBLE (GeSIDA 11720 study), the largest head-to-head, phase IV randomised clinical trial (RCT) investigating the 2-drug regimen Dovato compared to the 3-drug regimen Biktarvy for the treatment of HIV-1
Tickers: GSK, GILD
Executed On: Jul 31, 2024 at 09:30 AM EDT
A Third View: Investigating GSK's recently approved RSV vaccine AREXVY.
Ticker: GSK
Executed On: Jul 11, 2024 at 09:30 AM EDT
A Second View: Investigating GSK's recently approved RSV vaccine AREXVY.
Ticker: GSK
Executed On: Jul 10, 2024 at 02:00 PM EDT
Investigating GSK's recently approved RSV vaccine AREXVY.
Ticker: GSK
Executed On: Jul 09, 2024 at 12:30 PM EDT
A Third Opinion: Discussing the new long-term data on the Shingrix shingles vaccine
Ticker: GSK
Executed On: May 08, 2024 at 10:00 AM EDT
A Second Look: Discussing the potential of Jemperli (dostarlimab) plus chemotherapy, with the addition of Zejula (niraparib) maintenance for patients with primary advanced or recurrent endometrial cancer.
Ticker: GSK
Executed On: May 07, 2024 at 05:00 PM EDT
A Second Opinion: Discussing the new long-term data on the Shingrix shingles vaccine
Ticker: GSK
Executed On: May 02, 2024 at 12:30 PM EDT
A Third Look: Delving into the phase 2 interim data from CureVac and GSK's Seasonal Influenza Vaccine Development Program
Tickers: CVAC, GSK
Executed On: Apr 30, 2024 at 02:00 PM EDT
Discussing the new long-term data on the Shingrix shingles vaccine
Ticker: GSK
Executed On: Apr 30, 2024 at 09:30 AM EDT
A Second Look: Delving into the phase 2 interim data from CureVac and GSK's Seasonal Influenza Vaccine Development Program
Tickers: CVAC, GSK
Executed On: Apr 26, 2024 at 04:15 PM EDT
Delving into the phase 2 interim data from CureVac and GSK's Seasonal Influenza Vaccine Development Program
Tickers: CVAC, GSK
Executed On: Apr 25, 2024 at 11:00 AM EDT
A Third Look: Discussing the results from the interim analysis of the DREAMM-8 phase III head-to-head trial evaluating Blenrep in combination with PomDex, as a second line and later treatment for relapsed or refractory multiple myeloma.
Ticker: GSK
Executed On: Apr 17, 2024 at 08:30 AM EDT
Discussing the potential of Jemperli (dostarlimab) plus chemotherapy, with the addition of Zejula (niraparib) maintenance for patients with primary advanced or recurrent endometrial cancer.
Ticker: GSK
Executed On: Apr 03, 2024 at 09:30 AM EDT
A Second Look: Discussing the results from the interim analysis of the DREAMM-8 phase III head-to-head trial evaluating Blenrep in combination with PomDex, as a second line and later treatment for relapsed or refractory multiple myeloma.
Ticker: GSK
Executed On: Apr 05, 2024 at 05:00 PM EDT
Discussing the results from the interim analysis of the DREAMM-8 phase III head-to-head trial evaluating Blenrep in combination with PomDex, as a second line and later treatment for relapsed or refractory multiple myeloma.
Ticker: GSK
Executed On: Mar 28, 2024 at 10:25 AM EDT
A Third Look: Discussing the headline results from the EAGLE-1 phase III trial for Gepotidacin an experimental antibiotic for treatment of Gonorrhoea
Ticker: GSK
Executed On: Mar 19, 2024 at 02:00 PM EDT
A Second Look: Discussing the headline results from the EAGLE-1 phase III trial for Gepotidacin an experimental antibiotic for treatment of Gonorrhoea
Ticker: GSK
Executed On: Mar 05, 2024 at 02:00 PM EST
A Third Look: Discussing the LATITUDE phase III interim trial data on Cabenuva (cabotegravir, rilpivirine) for treatment of HIV
Tickers: GSK, ViiV Healthcare
Executed On: Feb 29, 2024 at 04:00 PM EST
A Second Look: Discussing the LATITUDE phase III interim trial data on Cabenuva (cabotegravir, rilpivirine) for treatment of HIV
Tickers: GSK, ViiV Healthcare
Executed On: Feb 29, 2024 at 03:00 PM EST
Discussing the headline results from the EAGLE-1 phase III trial for Gepotidacin an experimental antibiotic for treatment of Gonorrhoea
Ticker: GSK
Executed On: Feb 28, 2024 at 05:00 PM EST
Discussing the LATITUDE phase III interim trial data on Cabenuva (cabotegravir, rilpivirine) for treatment of HIV
Tickers: GSK, PFE
Executed On: Feb 28, 2024 at 10:30 AM EST
A Third Opinion: Discussing the potential of Ojjaara (momelotinib), a JAK inhibitor recently approved by the FDA for the treatment of myelofibrosis and anemia.
Ticker: GSK
Executed On: Jan 04, 2024 at 01:00 PM EST
A third look at the RSV current treatment landscape including available vaccines from GSK (Arexvy) and Pfizer (Abryvso)
Tickers: PFE, GSK
Executed On: Dec 22, 2023 at 10:00 AM EST
A Second Prescriber check-in on GSK's PD-1 inhibitor, JEMPERLI (dostarlimab-gxly) for patients with endometrial cancer
Ticker: GSK
Executed On: Dec 20, 2023 at 07:00 PM EST
A second look at the RSV current treatment landscape including available vaccines from GSK (Arexvy) and Pfizer (Abryvso)
Tickers: PFE, GSK
Executed On: Dec 14, 2023 at 12:30 PM EST
A look at the RSV current treatment landscape including available vaccines from GSK (Arexvy) and Pfizer (Abryvso)
Tickers: PFE, GSK
Executed On: Dec 13, 2023 at 10:30 AM EST
Prescriber check-in on GSK's PD-1 inhibitor, JEMPERLI (dostarlimab-gxly) for patients with endometrial cancer
Ticker: GSK
Executed On: Dec 11, 2023 at 01:00 PM EST
A Second Opinion: Discussing the potential of Ojjaara (momelotinib), a JAK inhibitor recently approved by the FDA for the treatment of myelofibrosis and anemia.
Ticker: GSK
Executed On: Nov 30, 2023 at 01:30 PM EST
Discussing the potential of Ojjaara (momelotinib), a JAK inhibitor recently approved by the FDA for the treatment of myelofibrosis and anemia.
Ticker: GSK
Executed On: Nov 29, 2023 at 09:00 AM EST
A Second Look: Discussing the use of JESDUVROQ (daprodustat) in adult patients on dialysis for the treatment of anemia due to CKD
Ticker: GSK
Executed On: Aug 16, 2023 at 11:00 AM EDT
Discussing the use of JESDUVROQ (daprodustat) in adult patients on dialysis for the treatment of anemia due to CKD
Ticker: GSK
Executed On: Aug 14, 2023 at 02:00 PM EDT
Discussing the potential use of momelotinib, a potent ACVR1/ALK2 and JAK1/2 inhibitor from GSK for patients with Myelofibrosis
Ticker: GSK
Executed On: Aug 03, 2023 at 11:00 AM EDT
A second look at the current treatment landscape of RSV with a focus on Bavarian Nordic's MVA-BN RSV and GSK's newly approved Arexvy
Tickers: BVNRY, GSK
Executed On: Jul 06, 2023 at 09:00 AM EDT
A look at the current treatment landscape of RSV with a focus on Bavarian Nordic's MVA-BN RSV and GSK's newly approved Arexvy
Tickers: GSK, BVNRY
Executed On: Jun 14, 2023 at 03:00 PM EDT
A Second View: Prescriber check in on the use of Brexafemme in treating VVC
Ticker: GSK
Executed On: Apr 04, 2023 at 04:00 PM EDT
Prescriber check in on the use of Brexafemme in treating VVC
Ticker: GSK
Executed On: Apr 03, 2023 at 05:00 PM EDT
A second discussion on the potential of GSK's RSV vaccine
Ticker: GSK
Executed On: Mar 16, 2023 at 03:00 PM EDT
Discussing the potential of GSK's RSV vaccine
Ticker: GSK
Executed On: Mar 14, 2023 at 01:00 PM EDT
A third look at the use and potential of Daprodustat in adult patients with anemia due to CKD that on dialysis and not on dialysis with reference to the positive results from the Phase 3 ASCEND studies.
Ticker: GSK
Executed On: Mar 08, 2023 at 04:00 PM EST
A Second look at the use and potential of Daprodustat in adult patients with anemia due to CKD that on dialysis and not on dialysis with reference to the positive results from the Phase 3 ASCEND studies.
Ticker: GSK
Executed On: Mar 06, 2023 at 11:00 AM EST
Discussing GSK's Jemperli (Dostarlimab) in treating patients with endometrial cancer
Ticker: GSK
Executed On: Feb 27, 2023 at 06:00 PM EST
Discussing the potential of Daprodustat in adult patients with anemia due to CKD that on dialysis and not on dialysis with reference to the positive results from the Phase 3 ASCEND studies.
Ticker: GSK
Executed On: Feb 10, 2023 at 12:00 PM EST
A Third View: Discussing the current treatment landscape for tuberculosis and new therapies in development including GSK3036656 in development from GSK in light of the recent positive results from a Phase IIa study.
Ticker: GSK
Executed On: Jan 12, 2023 at 10:00 AM EST
A second look: Discussing new therapies in development including tebipenem pivoxil hydrobromide (tebipenem HBr), an oral carbapenem antibiotic currently in development by GSK & Spero to potentially treat complicated urinary tract infections
Tickers: GSK, SPRO
Executed On: Dec 16, 2022 at 09:00 AM EST
A Second View: Discussing the current treatment landscape for tuberculosis and new therapies in development including GSK3036656 in development from GSK in light of the recent positive results from a Phase IIa study.
Ticker: GSK
Executed On: Dec 05, 2022 at 06:45 PM EST
Discussing the current treatment landscape for tuberculosis and new therapies in development including GSK3036656 in development from GSK in light of the recent positive results from a Phase IIa study.
Ticker: GSK
Executed On: Dec 05, 2022 at 04:00 PM EST
Examining the recent FDA approval for GSK's TDAP vaccine Boostrix in third trimester pregnancies.
Ticker: GSK
Executed On: Nov 21, 2022 at 10:00 AM EST
A third look: Discussing the potential of Gepotidacin for the treatment of uncomplicated urogenital gonorrhea and the Phase 2 results.
Ticker: GSK
Executed On: Nov 18, 2022 at 01:00 PM EST
A second look: Discussing the potential of Gepotidacin for the treatment of uncomplicated urogenital gonorrhea and the Phase 2 results.
Ticker: GSK
Executed On: Nov 17, 2022 at 10:00 AM EST
A third look at the potential of Gepotidacin in uncomplicated urinary tract infections and the EAGLE-2 and EAGLE-3 trials of Gepotidacin compared to current standard of care, nitrofurantoin.
Ticker: GSK
Executed On: Nov 16, 2022 at 03:00 PM EST
Discussing the potential of Gepotidacin for the treatment of uncomplicated urogenital gonorrhea and the Phase 2 results.
Ticker: GSK
Executed On: Nov 16, 2022 at 12:00 PM EST
A second look at the potential of Gepotidacin in uncomplicated urinary tract infections and the EAGLE-2 and EAGLE-3 trials of Gepotidacin compared to current standard of care, nitrofurantoin.
Ticker: GSK
Executed On: Nov 09, 2022 at 01:30 PM EST
Discussing new therapies in development including tebipenem pivoxil hydrobromide (tebipenem HBr), an oral carbapenem antibiotic currently in development by GSK & Spero to potentially treat complicated urinary tract infections
Tickers: SPRO, GSK
Executed On: Nov 09, 2022 at 01:30 PM EST
A look at the potential of Gepotidacin in uncomplicated urinary tract infections and the EAGLE-2 and EAGLE-3 trials of Gepotidacin compared to current standard of care, nitrofurantoin.
Ticker: GSK
Executed On: Nov 08, 2022 at 07:00 PM EST
Discussing the standard of care of patients with NSCLC, with a focus on PD-1/PD-L1 inhibitors and the potential of GSK's dostarlimab in this space.
Ticker: GSK
Executed On: Oct 19, 2022 at 04:00 PM EDT
Discussing GSK's ASCEND trial to assess the efficacy and safety profile of daprodustat with CKD Anemia
Ticker: GSK
Executed On: Oct 07, 2022 at 03:00 PM EDT
A second look at the P1 data presented at ESMO for ubamatamab, a CD3-targeting bispecific antibody under investigation for recurrent ovarian cancer
Tickers: REGN, AZN, CLVS, IMGN, GSK, RHHBY
Executed On: Sep 29, 2022 at 05:15 PM EDT
A look at Abstract-8019: Blenrep + nirogacestat in r/r Multiple myeloma (DREAMM-5 STUDY) - 2nd view
Tickers: SWTX, GSK
Executed On: May 25, 2022 at 01:00 PM EDT
A look at Abstract-8019: Blenrep + nirogacestat in r/r Multiple myeloma (DREAMM-5 STUDY)
Tickers: SWTX, GSK
Executed On: May 20, 2022 at 02:00 PM EDT
A Second Look: Discussing the recent label update for HIV treatment, Cabenuva (cabotegravir, rilpivirine)
Tickers: GSK, PFE
Executed On: Mar 29, 2022 at 11:00 AM EDT
Discussing the recent label update for HIV treatment, Cabenuva (cabotegravir, rilpivirine)
Tickers: GSK, PFE
Executed On: Mar 28, 2022 at 04:30 PM EDT

Upcoming & Overdue Catalysts (GSK)

Don’t see a catalyst related to the company you care about? Create your own!

Strategic Initiatives (GSK)

Don’t see a strategic initiative related to the company you care about? Create your own!